Biography
Dr Palace is Consultant Neurologist in Oxford and runs the regional MS service and General neurology for the Banbury area.
She is Lead for the national Congenital Myasthenia service and also runs a joint National Neuromyelitis Service with the Walton Centre Liverpool.
She is a clinical lead for the UK MS risk sharing scheme study assessing the long term effects of beta-interferon and Copaxone.
On Oct 2011 she has published over 80 papers and reviews.
Awards Training and Qualifications
- 1983 BM Honours and Clinical Distinction, SOTON
- 1986 MRCP, SOTON
- 1992 DM, SOTON
- 1995 Accredited Neurology
- 2000 FRCP
Jacqueline Palace
BM (Hons) FRCP DM
Consultant Neurologist and Professor of Clinical Neurology
- Oxford Multiple Sclerosis and Neuromyelitis Group
Neuromyelitus optica, multiple sclerosis and myasthenia
Research Summary
Dr. Palace leads the Oxford Multiple Sclerosis and Neuromyelitis Group. This comprises a regional clinical service and a clinical research group. Research topics include clinical treatment trials, immunological studies, biomarkers and imaging studies on neurodegeneration and its detection and association with inflammation. The group welcomes referrals of patients.
Sources of Funding
- MS Society 2008- 2011
- OHSRC 2011- 2012
- John Fell 2010- 2011
- UKCRN 2009- 2012
- Glaxo-Smith-Kline 2007- 2011
- Merck Serono 2010- 2012
- Bayer-Schering 2010- 2012
- Novartis 2010- 2012
- Biogen Idec 2007- 2012
- QIDIS: National Specialist Commissioning Team 2009- 2012
Recent publications
Myasthenic syndromes: mistaking genetic for acquired
Journal article
Henehan L. et al, (2026), Practical Neurology, 26, 164 - 168
Prediction of relapse in myelin oligodendrocyte glycoprotein antibody-associated disease: external validation of the MOG-AR score.
Journal article
Yeh WZ. et al, (2026), J Neurol, 273
Lessons Learned: Quality Analysis of Optical Coherence Tomography in Neuromyelitis Optica
Journal article
Salih H. et al, (2026), Annals of Clinical and Translational Neurology, 13, 581 - 592
Predictive factors for immunosuppression-associated severe and opportunistic infections in AQP4-IgG Neuromyelitis Optica Spectrum Disorder
Journal article
Greco G. et al, (2026), Multiple Sclerosis Journal, 32, 326 - 337
Congenital myasthenic syndrome: is it time for a name change to genetic myasthenic syndrome?
Journal article
Ramdas S. et al, (2026), Brain